Biosimilars

The Pharmacy Times® Biosimilars Resource Center is a comprehensive resource for clinical news and expert insights on issues related to biosimilar drugs, a biological product that is highly similar to a reference biologic for which there are no clinically meaningful differences in terms of safety, purity, and efficacy.

Latest News

Adalimumab (Humira) biosimilar (Hyrimoz) -- Image credit: luchschenF | stock.adobe.com
Switching From Reference Adalimumab to Biosimilar Shows No Major Differences in Patients With RA, PsA

August 28th 2025

Biosimilars can be a more affordable and accessible treatment option for patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA).

Denosumab (Xgeva) -- Image credit: Tenacity_1987 | stock.adobe.com
LY01011, Biosimilar of Denosumab, Meets Primary End Point in Study

August 26th 2025

GLP-1 dulaglutide (Trulicity) -- Image credit: Edugrafo | stock.adobe.com
Dulaglutide Biosimilar Achieves Equivalent Efficacy in HbA1c Reduction in Patients With T2DM

August 22nd 2025

Image credit: yodiyim | stock.adobe.com
Study: High Similarity, Efficacy Between Tocilizumab Biosimilar and Reference Product in RA

August 21st 2025

Navigating Biosimilars and 505(b)(2) Drugs in Oncology: Operational, Clinical, and Policy Strategies for Pharmacists
Navigating Biosimilars and 505(b)(2) Drugs in Oncology: Operational, Clinical, and Policy Strategies for Pharmacists

August 15th 2025

<1
...
1718192021